Figure 4: Distribution of AP in the study groups. In patients with BMD (no tumor) 100.0% were of normal activity, 0.0% were pathological elevated. Patients with tumor but without bone metastases showed normal activity in 86.67% and elevated levels of AP in 13.33%. The AP levels were normal in 6% of all patients with known bone metastases and elevated in 94%